Randomized Crossover Pharmacokinetic Evaluation of Subcutaneous Versus Intravenous Granisetron in Cancer Patients

Phase 2 Completed 31 enrolled Clinica Universidad de Navarra, Universidad de Navarra

NaSingle-groupOpen-labelSupportive care

Summary

Objective: to evaluate the bioavailability of subcutaneous granisetron.Patients receiving platinum-based chemotherapy will be randomized to receive granisetron 3 mg either subcutaneously or intravenously in a crossover manner during two cycles. Blood and urine samples will be collected after each cycle.

Timeline

Start: 2005-04
Primary completion: 2005-11
Completion: 2005-11

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Granisetron	Other / unclassified	3 mg	Subcutaneous

Indications

No indication recorded.